COPD患者急性心肌梗死后的β受体阻滞剂使用与临床结局
这项前瞻性纵向队列研究纳入美国18家BLOCK-COPD网络医院中因AMI接受心导管检查的COPD患者,随访6个月。3531例接受心导管检查的患者中COPD患病率为17.1%(95%CI 15.8%-18.4%),579例COPD合并AMI患者中502例(86.7%)出院时处方β受体阻滞剂;最终分析562例,中位年龄70.0岁(范围38.0-94.0岁),男性329例(58.5%)。出院带β受体阻滞剂者主要终点(全因死亡、血运重建或住院)风险无增加(HR 1.01;95%CI 0.66-1.54;P=.96),心血管事件(HR 1.11;95%CI 0.65-1.92;P=.69)、COPD相关或呼吸事件(HR 0.75;95%CI 0.34-1.66;P=.48)、COPD急性加重治疗(率比1.01;95%CI 0.53-1.91;P=.98)均无显著差异。作者结论认为这些发现支持在COPD合并近期AMI患者中使用β受体阻滞剂。
要点
- COPD合并AMI患者出院时处方β受体阻滞剂与主要复合终点(全因死亡、血运重建或住院)风险无增加相关(HR 1.01;95%CI 0.66-1.54;P=.96)。
- β受体阻滞剂与心血管事件风险无显著相关(HR 1.11;95%CI 0.65-1.92;P=.69)。
- β受体阻滞剂与COPD相关或呼吸事件风险无显著相关(HR 0.75;95%CI 0.34-1.66;P=.48)。
- β受体阻滞剂与COPD急性加重治疗率无显著相关(率比1.01;95%CI 0.53-1.91;P=.98)。
- 作者结论认为这些发现支持在COPD合并近期AMI患者中使用β受体阻滞剂。
适用人群与场景
- 年龄35岁及以上、因AMI接受心导管检查的COPD患者,来自美国18家BLOCK-COPD网络医院,2020年6月至2022年5月入组。
- 最终分析562例COPD合并AMI患者,中位年龄70.0岁(范围38.0-94.0岁),男性329例(58.5%)。
研究设计与关键结果
- 研究类型:前瞻性纵向队列研究,随访6个月,18家BLOCK-COPD网络医院,美国,2020年6月至2022年5月。
- 3531例因AMI接受心导管检查的患者中COPD患病率为17.1%(95%CI 15.8%-18.4%);579例COPD合并AMI患者中502例(86.7%)出院时处方β受体阻滞剂;553/579例(95.5%)有随访信息。
- 主要终点(全因死亡、血运重建或住院复合终点):出院带β受体阻滞剂者风险无增加(HR 1.01;95%CI 0.66-1.54;P=.96)。
- 次要终点心血管事件:HR 1.11(95%CI 0.65-1.92;P=.69);COPD相关或呼吸事件:HR 0.75(95%CI 0.34-1.66;P=.48);COPD急性加重治疗:率比1.01(95%CI 0.53-1.91;P=.98)。
证据类型、等级与局限
- 证据类型:前瞻性纵向队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,COPD合并AMI患者出院时处方β受体阻滞剂与不良结局风险增加无关,这些发现支持在此类患者中使用β受体阻滞剂。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: While β-blockers are associated with decreased mortality in cardiovascular disease (CVD), exacerbation-prone patients with chronic obstructive pulmonary disease (COPD) who received metoprolol in the Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (BLOCK-COPD) trial experienced increased risk of exacerbations requiring hospitalization. However, the study excluded individuals with established indications for the drug, raising questions about the overall risk and benefit in patients with COPD following acute myocardial infarction (AMI).
OBJECTIVE: To investigate whether β-blocker prescription at hospital discharge is associated with increased risk of mortality or adverse cardiopulmonary outcomes in patients with COPD and AMI.
DESIGN, SETTING, AND PARTICIPANTS: This prospective, longitudinal cohort study with 6 months of follow-up enrolled patients aged 35 years or older with COPD who underwent cardiac catheterization for AMI at 18 BLOCK-COPD network hospitals in the US from June 2020 through May 2022.
EXPOSURE: Prescription for any β-blocker at hospital discharge.
MAIN OUTCOMES AND MEASURES: The primary outcome was time to the composite outcome of death or all-cause hospitalization or revascularization. Secondary outcomes included death, hospitalization, or revascularization for CVD events, death or hospitalization for COPD or respiratory events, and treatment for COPD exacerbations.
RESULTS: Among 3531 patients who underwent cardiac catheterization for AMI, prevalence of COPD was 17.1% (95% CI, 15.8%-18.4%). Of 579 total patients with COPD and AMI, 502 (86.7%) were prescribed a β-blocker at discharge. Among the 562 patients with COPD included in the final analysis, median age was 70.0 years (range, 38.0-94.0 years) and 329 (58.5%) were male; 553 of the 579 patients (95.5%) had follow-up information. Among those discharged with β-blockers, there was no increased risk of the primary end point of all-cause mortality, revascularization, or hospitalization (hazard ratio [HR], 1.01; 95% CI, 0.66-1.54; P = .96) or of cardiovascular events (HR, 1.11; 95% CI, 0.65-1.92; P = .69), COPD-related or respiratory events (HR, 0.75; 95% CI, 0.34-1.66; P = .48), or treatment for COPD exacerbations (rate ratio, 1.01; 95% CI, 0.53-1.91; P = .98).
CONCLUSIONS AND RELEVANCE: In this cohort study, β-blocker prescription at hospital discharge was not associated with increased risk of adverse outcomes in patients with COPD and AMI. These findings support use of β-blockers in patients with COPD and recent AMI.
参考来源
- LaFon DC, Helgeson ES, Lindberg S, et al. β-Blocker Use and Clinical Outcomes in Patients With COPD Following Acute Myocardial Infarction. JAMA Netw Open. 2024. PMID: 38771577. doi:10.1001/jamanetworkopen.2024.7535
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。